Knowns and unknowns of identifications management of depressed brain tumor patients

Written by Aistė Pranckevičienė & Adomas Bunevičius

Malignant brain tumors (BT) are often devastating diseases associated with short life expectancy and progressive impairment of functional status and quality of life. Depression is a highly prevalent complication among patients with established BT diagnosis, with reported point-prevalence rates approaching 50% [1]. A constantly increasing body of evidence suggests that depression is related to significant impairment of health-related quality of life [2], worse treatment outcomes [3] and shorter survival [4] of BT patients. Furthermore, depressed patients are at risk for adverse health behaviors and impaired compliance with treatment recommendations [5]. From a clinical perspective, early recognition of depressed BT patients...

To view this content, please register now for access

It's completely free